title: Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions.
abstract: Bioresorbable vascular scaffolds (BVS) represent a novel therapeutic option for the treatment of coronary artery diseases. The objective of this study was to evaluate the feasibility of BVS implantation in complex chronic total occlusions (CTO).
  
  
  
  The present report is a multicentre registry evaluating results after BVS deployment in challenging CTO lesions, defined as J-CTO score ≥2 (difficult or very difficult). A total of 105 patients were included in the present analysis. The mean J-CTO score was 2.61 (difficult 52.4%, very difficult 47.6%). Device success and procedural success rates were 98.1% and 97.1%, respectively. The retrograde approach was used in 25.7% of cases. After wire crossing, predilatation was performed in all cases with a mean predilatation balloon diameter of 2.73±0.43 mm. The mean scaffold length was 59.75±25.85 mm, with post-dilatation performed in 89.5% of the cases and a mean post-dilatation balloon diameter of 3.35±0.44 mm. Post-PCI minimal lumen diameter was 2.50±0.51 mm and percentage diameter stenosis 14.53±10.31%. At six-month follow-up, a total of three events were reported: one periprocedural myocardial infarction, one late scaffold thrombosis and one additional target lesion revascularisation.
  
  
  
  The present report suggests the feasibility of BVS implantation in complex CTO lesions, given adequate lesion preparation and post-dilatation, with good acute angiographic results and midterm clinical outcomes.
authors.affiliation: National Heart Centre Singapore, Singapore.
authors.forename: Jiang Ming
authors.initials: JM
authors.lastname: Fam
authors.forename: Soledad
authors.initials: S
authors.lastname: Ojeda
authors.forename: Roberto
authors.initials: R
authors.lastname: Garbo
authors.forename: Azeem
authors.initials: A
authors.lastname: Latib
authors.forename: Alessio
authors.initials: A
authors.lastname: La Manna
authors.forename: Beatriz
authors.initials: B
authors.lastname: Vaquerizo
authors.forename: Marouane
authors.initials: M
authors.lastname: Boukhris
authors.forename: Georgios J
authors.initials: GJ
authors.lastname: Vlachojannis
authors.forename: Robert-Jan
authors.initials: RJ
authors.lastname: van Geuns
authors.forename: Babu
authors.initials: B
authors.lastname: Ezhumalai
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Kawamoto
authors.forename: Jors
authors.initials: J
authors.lastname: van der Sijde
authors.forename: Cordula
authors.initials: C
authors.lastname: Felix
authors.forename: Manuel
authors.initials: M
authors.lastname: Pan
authors.forename: Roberta
authors.initials: R
authors.lastname: Serdoz
authors.forename: Giacomo Giovanni
authors.initials: GG
authors.lastname: Boccuzzi
authors.forename: Marcella
authors.initials: M
authors.lastname: De Paolis
authors.forename: Gennaro
authors.initials: G
authors.lastname: Sardella
authors.forename: Massimo
authors.initials: M
authors.lastname: Mancone
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
authors.forename: Pieter C
authors.initials: PC
authors.lastname: Smits
authors.forename: Carlo
authors.initials: C
authors.lastname: Di Mario
authors.forename: Ashok
authors.initials: A
authors.lastname: Seth
authors.forename: Antonio
authors.initials: A
authors.lastname: Serra
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
authors.forename: Patrick
authors.initials: P
authors.lastname: Serruys
authors.forename: Alfredo R
authors.initials: AR
authors.lastname: Galassi
authors.forename: Felix
authors.initials: F
authors.lastname: Zijlstra
authors.forename: Nicolas M
authors.initials: NM
authors.lastname: Van Mieghem
authors.forename: Roberto
authors.initials: R
authors.lastname: Diletti
mesh_terms: D020341:Absorbable Implants; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003324:Coronary Artery Disease / Q000628:therapy*; D054059:Coronary Occlusion / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods; D012042:Registries; D054457:Tissue Scaffolds / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus